306 related articles for article (PubMed ID: 27226207)
21. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
Murai J; Pommier Y
Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
[TBL] [Abstract][Full Text] [Related]
22. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
[TBL] [Abstract][Full Text] [Related]
23. Reverse the Resistance to PARP Inhibitors.
Kim Y; Kim A; Sharip A; Sharip A; Jiang J; Yang Q; Xie Y
Int J Biol Sci; 2017; 13(2):198-208. PubMed ID: 28255272
[TBL] [Abstract][Full Text] [Related]
24. PARPi focus the spotlight on replication fork protection in cancer.
Schlacher K
Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
[TBL] [Abstract][Full Text] [Related]
25. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
[TBL] [Abstract][Full Text] [Related]
26. Exploration of poly (ADP-ribose) polymerase inhibitor resistance in the treatment of BRCA1/2-mutated cancer.
Wu S; Yao X; Sun W; Jiang K; Hao J
Genes Chromosomes Cancer; 2024 May; 63(5):e23243. PubMed ID: 38747337
[TBL] [Abstract][Full Text] [Related]
27. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
28. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
29. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
30. Predictive biomarkers for cancer therapy with PARP inhibitors.
Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
[TBL] [Abstract][Full Text] [Related]
31. PARP Inhibitors: Extending Benefit Beyond
Pilié PG; Gay CM; Byers LA; O'Connor MJ; Yap TA
Clin Cancer Res; 2019 Jul; 25(13):3759-3771. PubMed ID: 30760478
[TBL] [Abstract][Full Text] [Related]
32. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
33. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
[TBL] [Abstract][Full Text] [Related]
34. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
Helleday T
Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
[TBL] [Abstract][Full Text] [Related]
35. Exploiting replication gaps for cancer therapy.
Cong K; Cantor SB
Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
[TBL] [Abstract][Full Text] [Related]
36. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
Mohyuddin GR; Aziz M; Britt A; Wade L; Sun W; Baranda J; Al-Rajabi R; Saeed A; Kasi A
BMC Cancer; 2020 Jun; 20(1):507. PubMed ID: 32493233
[TBL] [Abstract][Full Text] [Related]
37.
Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
[TBL] [Abstract][Full Text] [Related]
38. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Lightfoot M; Montemorano L; Bixel K
Curr Oncol Rep; 2020 Feb; 22(3):29. PubMed ID: 32067102
[TBL] [Abstract][Full Text] [Related]
39. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
Xavier MA; Rezende F; Titze-de-Almeida R; Cornelissen B
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439854
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Ning J; Wakimoto H
Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
